Summary of Study ST000048
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000046. The data can be accessed directly via it's Project DOI: 10.21228/M84S36 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000048 |
| Study Title | Metabolomic & lipidomic profiles in response to exogenous insulin & GLP-1 infusions during prolonged fasting (GCMS) |
| Study Type | Timecourse |
| Study Summary | This application requests funding to access state-of-the-art metabolomics and lipidomic platforms at the NIH West Coast Metabolomics Center to analyze plasma samples from recent insulin and glucagon-like peptide-1 (GLP-1) infusion experiments performed in prolong-fasted elephant seals. This suite of studies was designed to better assess the mechanisms contributing to the onset of an insulin resistantlike condition induced by prolonged food deprivation/starvation in mammals. Because elephant seals have evolved robust physiological mechanisms that have allowed them to naturally tolerate such protracted bouts of fasting, they provide an ideal model to address our central hypothesis that increased lipid utilization late in the fast contributes to insulin resistance in elephant seals. Insulin resistance is a common consequence of fasting in mammals and, while the mechanisms by which it manifests are still unclear, a metabolic shift favoring increased mobilization and utilization of lipids during prolonged food deprivation may be a principal causative factor. Insulin resistance has a negative connotation due to its association with obesity and diabetes among humans, but it has been suggested to be an adaptive response to food deprivation. |
| Institute | University of California, Davis |
| Department | GBSF |
| Laboratory | WCMC Metabolomics Core |
| Last Name | Fiehn |
| First Name | Oliver |
| Address | 451 Health Sci Drive, Davis, CA 95616 |
| ofiehn@ucdavis.edu | |
| Phone | 1-530-752-8258 |
| Submit Date | 2014-03-25 |
| Num Groups | 5 |
| Total Subjects | 117 |
| Study Comments | 5 general classes are designed in the experiment: #1 - A=No GLP1/ Late GTT #2 - B=GLP1 (Low Dose) #3 - C=GLP1 (High Dose) #4 - IL- Early Fasting Insulin Infusion #5 - IE- Late Fasting Insulin Infusion Each of the 5 classes has 6 timepoints (5x6): T1 - 0 min T2 - 10 min T3 - 30 min T4 - 60 min T5 - 120 min Each timepoint had 5 animals (5 animals x 5 classes x 6 timepoints = 150 total Because certain animals and timepoints had to be excluded 108 measurments remain. The experiment also contains 9 technical replicates of pooled samples (pool) The total sample number is 108 (biological) + 9 pooled samples = 117 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | cdf |
| Uploaded File Size | 1.8 G |
| Analysis Type Detail | GC-MS |
| Release Date | 2014-04-24 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000046 |
| Project DOI: | doi: 10.21228/M84S36 |
| Project Title: | Metabolomic & lipidomic profiles in response to exogenous insulin & GLP-1 infusions during prolonged fasting |
| Project Type: | Timecourse |
| Project Summary: | This application requests funding to access state-of-the-art metabolomics and lipidomic platforms at the NIH West Coast Metabolomics Center to analyze plasma samples from recent insulin and glucagon-like peptide-1 (GLP-1) infusion experiments performed in prolong-fasted elephant seals. This suite of studies was designed to better assess the mechanisms contributing to the onset of an insulin resistantlike condition induced by prolonged food deprivation/starvation in mammals. Because elephant seals have evolved robust physiological mechanisms that have allowed them to naturally tolerate such protracted bouts of fasting, they provide an ideal model to address our central hypothesis that increased lipid utilization late in the fast contributes to insulin resistance in elephant seals. Insulin resistance is a common consequence of fasting in mammals and, while the mechanisms by which it manifests are still unclear, a metabolic shift favoring increased mobilization and utilization of lipids during prolonged food deprivation may be a principal causative factor. Insulin resistance has a negative connotation due to its association with obesity and diabetes among humans, but it has been suggested to be an adaptive response to food deprivation. |
| Institute: | University of California, Merced |
| Department: | School of Natural Sciences |
| Laboratory: | Molecular and Cellular Biology, Natural Sciences |
| Last Name: | Ortiz |
| First Name: | Rudy |
| Address: | 5200 N. Lake Rd.; Merced, CA 95343 |
| Email: | rortiz@ucmerced.edu |
| Phone: | 209.228.2964 |
Subject:
| Subject ID: | SU000066 |
| Subject Type: | Animal |
| Subject Species: | Mirounga angustirostris |
| Taxonomy ID: | 9716 |
| Species Group: | Mammal |
Factors:
Subject type: Animal; Subject species: Mirounga angustirostris (Factor headings shown in green)
| mb_sample_id | local_sample_id | Treatment | Minutes |
|---|---|---|---|
| SA002026 | IL04-0 | Early Fasting Insulin Infusion | 0 |
| SA002027 | IL03-0 | Early Fasting Insulin Infusion | 0 |
| SA002028 | IL01-0 | Early Fasting Insulin Infusion | 0 |
| SA002029 | IL05-0 | Early Fasting Insulin Infusion | 0 |
| SA002030 | IL02-0 | Early Fasting Insulin Infusion | 0 |
| SA002031 | IL03-10 | Early Fasting Insulin Infusion | 10 |
| SA002032 | IL02-10 | Early Fasting Insulin Infusion | 10 |
| SA002033 | IL05-10 | Early Fasting Insulin Infusion | 10 |
| SA002034 | IL01-10 | Early Fasting Insulin Infusion | 10 |
| SA002035 | IL04-10 | Early Fasting Insulin Infusion | 10 |
| SA002036 | IL04-120 | Early Fasting Insulin Infusion | 120 |
| SA002037 | IL05-120 | Early Fasting Insulin Infusion | 120 |
| SA002038 | IL03-120 | Early Fasting Insulin Infusion | 120 |
| SA002039 | IL01-120 | Early Fasting Insulin Infusion | 120 |
| SA002040 | IL02-120 | Early Fasting Insulin Infusion | 120 |
| SA002041 | IL05-30 | Early Fasting Insulin Infusion | 30 |
| SA002042 | IL01-30 | Early Fasting Insulin Infusion | 30 |
| SA002043 | IL03-30 | Early Fasting Insulin Infusion | 30 |
| SA002044 | IL04-30 | Early Fasting Insulin Infusion | 30 |
| SA002045 | IL02-30 | Early Fasting Insulin Infusion | 30 |
| SA002046 | IL03-60 | Early Fasting Insulin Infusion | 60 |
| SA002047 | IL04-60 | Early Fasting Insulin Infusion | 60 |
| SA002048 | IL02-60 | Early Fasting Insulin Infusion | 60 |
| SA002049 | IL01-60 | Early Fasting Insulin Infusion | 60 |
| SA002050 | C03-0 | GLP1 (High Dose) | 0 |
| SA002051 | C02-0 | GLP1 (High Dose) | 0 |
| SA002052 | C04-0 | GLP1 (High Dose) | 0 |
| SA002053 | C01-0 | GLP1 (High Dose) | 0 |
| SA002054 | C04-10 | GLP1 (High Dose) | 10 |
| SA002055 | C02-10 | GLP1 (High Dose) | 10 |
| SA002056 | C03-10 | GLP1 (High Dose) | 10 |
| SA002057 | C01-10 | GLP1 (High Dose) | 10 |
| SA002058 | C02-120 | GLP1 (High Dose) | 120 |
| SA002059 | C04-120 | GLP1 (High Dose) | 120 |
| SA002060 | C03-120 | GLP1 (High Dose) | 120 |
| SA002061 | C01-120 | GLP1 (High Dose) | 120 |
| SA002062 | C02-30 | GLP1 (High Dose) | 30 |
| SA002063 | C03-30 | GLP1 (High Dose) | 30 |
| SA002064 | C01-30 | GLP1 (High Dose) | 30 |
| SA002065 | C04-30 | GLP1 (High Dose) | 30 |
| SA002066 | C01-60 | GLP1 (High Dose) | 60 |
| SA002067 | C02-60 | GLP1 (High Dose) | 60 |
| SA002068 | C03-60 | GLP1 (High Dose) | 60 |
| SA002069 | C04-60 | GLP1 (High Dose) | 60 |
| SA002070 | B02-0 | GLP1 (Low Dose) | 0 |
| SA002071 | B01-0 | GLP1 (Low Dose) | 0 |
| SA002072 | B03-0 | GLP1 (Low Dose) | 0 |
| SA002073 | B01-10 | GLP1 (Low Dose) | 10 |
| SA002074 | B03-10 | GLP1 (Low Dose) | 10 |
| SA002075 | B02-10 | GLP1 (Low Dose) | 10 |
| SA002076 | B01-120 | GLP1 (Low Dose) | 120 |
| SA002077 | B02-120 | GLP1 (Low Dose) | 120 |
| SA002078 | B03-120 | GLP1 (Low Dose) | 120 |
| SA002079 | B03-30 | GLP1 (Low Dose) | 30 |
| SA002080 | B01-30 | GLP1 (Low Dose) | 30 |
| SA002081 | B02-30 | GLP1 (Low Dose) | 30 |
| SA002082 | B02-60 | GLP1 (Low Dose) | 60 |
| SA002083 | B03-60 | GLP1 (Low Dose) | 60 |
| SA002084 | B01-60 | GLP1 (Low Dose) | 60 |
| SA002085 | IE05-0 | Late Fasting Insulin Infusion | 0 |
| SA002086 | IE03-0 | Late Fasting Insulin Infusion | 0 |
| SA002087 | IE02-0 | Late Fasting Insulin Infusion | 0 |
| SA002088 | IE01-0 | Late Fasting Insulin Infusion | 0 |
| SA002089 | IE04-0 | Late Fasting Insulin Infusion | 0 |
| SA002090 | IE03-10 | Late Fasting Insulin Infusion | 10 |
| SA002091 | IE04-10 | Late Fasting Insulin Infusion | 10 |
| SA002092 | IE01-10 | Late Fasting Insulin Infusion | 10 |
| SA002093 | IE05-10 | Late Fasting Insulin Infusion | 10 |
| SA002094 | IE02-10 | Late Fasting Insulin Infusion | 10 |
| SA002095 | IE04-120 | Late Fasting Insulin Infusion | 120 |
| SA002096 | IE05-120 | Late Fasting Insulin Infusion | 120 |
| SA002097 | IE03-120 | Late Fasting Insulin Infusion | 120 |
| SA002098 | IE01-120 | Late Fasting Insulin Infusion | 120 |
| SA002099 | IE02-120 | Late Fasting Insulin Infusion | 120 |
| SA002100 | IE05-30 | Late Fasting Insulin Infusion | 30 |
| SA002101 | IE04-30 | Late Fasting Insulin Infusion | 30 |
| SA002102 | IE02-30 | Late Fasting Insulin Infusion | 30 |
| SA002103 | IE01-30 | Late Fasting Insulin Infusion | 30 |
| SA002104 | IE03-30 | Late Fasting Insulin Infusion | 30 |
| SA002105 | IE03-60 | Late Fasting Insulin Infusion | 60 |
| SA002106 | IE02-60 | Late Fasting Insulin Infusion | 60 |
| SA002107 | IE01-60 | Late Fasting Insulin Infusion | 60 |
| SA002108 | IE04-60 | Late Fasting Insulin Infusion | 60 |
| SA002109 | A05-0 | No GLP1/Late GTT | 0 |
| SA002110 | A02-0 | No GLP1/Late GTT | 0 |
| SA002111 | A03-0 | No GLP1/Late GTT | 0 |
| SA002112 | A01-0 | No GLP1/Late GTT | 0 |
| SA002113 | A04-0 | No GLP1/Late GTT | 0 |
| SA002114 | A03-10 | No GLP1/Late GTT | 10 |
| SA002115 | A04-10 | No GLP1/Late GTT | 10 |
| SA002116 | A01-10 | No GLP1/Late GTT | 10 |
| SA002117 | A05-10 | No GLP1/Late GTT | 10 |
| SA002118 | A02-10 | No GLP1/Late GTT | 10 |
| SA002119 | A01-120 | No GLP1/Late GTT | 120 |
| SA002120 | A02-120 | No GLP1/Late GTT | 120 |
| SA002121 | A03-120 | No GLP1/Late GTT | 120 |
| SA002122 | A05-120 | No GLP1/Late GTT | 120 |
| SA002123 | A04-120 | No GLP1/Late GTT | 120 |
| SA002124 | A03-30 | No GLP1/Late GTT | 30 |
| SA002125 | A01-30 | No GLP1/Late GTT | 30 |
Collection:
| Collection ID: | CO000049 |
| Collection Summary: | - |
| Sample Type: | Blood |
Treatment:
| Treatment ID: | TR000067 |
Sample Preparation:
| Sampleprep ID: | SP000062 |
| Sampleprep Summary: | - |
| Sampleprep Protocol Filename: | SOP_Extraction_of_Blood_Samples.pdf SOP_Derivatization_of_Samples-Standards_2.pdf |
| Processing Method: | Homogenization, protein precipitation via extraction, Solvent Removal w/ Speed Vac |
| Processing Storage Conditions: | On Ice |
| Extraction Method: | 3:3:2 Acetonitrile/Isopropanol/Water |
| Extract Concentration Dilution: | 30uL of plasma/ml |
| Extract Cleanup: | 1:1 Acetonitrile/Water |
| Extract Storage: | -20C Freezer |
| Sample Derivatization: | 10ul of 40mg/ml MeOX in pyridine, 91ul of MSTFA +FAMEs mixture |
| Sample Spiking: | FAMEs |
Combined analysis:
| Analysis ID | AN000084 |
|---|---|
| Analysis type | MS |
| Chromatography type | GC |
| Chromatography system | Agilent 6890N |
| Column | Restek corporation Rtx-5Sil MS |
| MS Type | EI |
| MS instrument type | GC-TOF |
| MS instrument name | Leco Pegasus III GC TOF |
| Ion Mode | POSITIVE |
| Units | Peak Area |
Chromatography:
| Chromatography ID: | CH000053 |
| Methods Filename: | SOP_GCTOF11082012.pdf |
| Instrument Name: | Agilent 6890N |
| Column Name: | Restek corporation Rtx-5Sil MS |
| Column Temperature: | 50-330oC |
| Flow Rate: | 1ml/min |
| Injection Temperature: | 50C ramped to 250C by 12C s-1 |
| Sample Injection: | 0.5uL |
| Oven Temperature: | 50C for 1 min, then ramped at 20C min-1 to 330C, held constant for 5 min |
| Transferline Temperature: | 230C |
| Washing Buffer: | Ethyl Acetate |
| Sample Loop Size: | 30 m length x 0.25 mm internal diameter |
| Randomization Order: | Excel generated |
| Chromatography Type: | GC |
MS:
| MS ID: | MS000065 |
| Analysis ID: | AN000084 |
| Instrument Name: | Leco Pegasus III GC TOF |
| Instrument Type: | GC-TOF |
| MS Type: | EI |
| Ion Mode: | POSITIVE |
| Ion Source Temperature: | 250°C |
| Ionization Energy: | -70eV |
| Mass Accuracy: | Nominal |
| Source Temperature: | 250°C |
| Scanning Range: | 80-500 Da |
| Acquisition Parameters File: | SOP_GCTOF11082012.pdf |
| Processing Parameters File: | Data_Dictionary_Fiehn_Laboratory_GCTOF_MS_primary_metabolism_09-27-2013_general.pdf |
